DK1750686T3 - Behandling af akutte refraktære epileptiske anfald med (R)-3-hydroxybutyrat - Google Patents
Behandling af akutte refraktære epileptiske anfald med (R)-3-hydroxybutyrat Download PDFInfo
- Publication number
- DK1750686T3 DK1750686T3 DK05742563.9T DK05742563T DK1750686T3 DK 1750686 T3 DK1750686 T3 DK 1750686T3 DK 05742563 T DK05742563 T DK 05742563T DK 1750686 T3 DK1750686 T3 DK 1750686T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- cultures
- ketogenic
- hydroxybutyrate
- induced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (8)
1. Ketogent materiale udvalgt fra (R)-3-hydroxybutyrat og salte heraf, estere og oligomerer, til anvendelse i behandlingen af akutte refraktære epileptiske anfald, hvor behandlingen initieres efter anfaldenes start for at stoppe apoptose.
2. Ketogent materiale ifølge krav 1 til anvendelse i behandlingen af status epilepticus, hvor behandlingen initieres efter start af status epilepticus.
3. Ketogent materiale til anvendelse i behandling ifølge krav 1 eller krav 2, hvor behandlingen producerer en ketose, hvor de totale niveauer for acetoacetat-og (R)-3-hydroxybutyratkoncentrationer i personens blod forhøjes over de normale tilførte niveauer til mellem 0,1 og 30 mM.
4. Ketogent materiale til anvendelse i behandling ifølge krav 3, hvor niveauet øges til mellem 0,3 og 15mM.
5. Ketogent materiale til anvendelse i behandling ifølge et hvilket som helst af krav 1 til 4, kendetegnet ved, at behandlingsdosen ligger i intervallet 5 til 5000 mg/kg kropsvægt.
6. Ketogent materiale til anvendelse i behandling ifølge et hvilket som helst af krav 1 til 5, hvor behandlingen administrerer materialet til en patient, der ikke er i stand til frivilligt at indtage materialer via munden.
7. Ketogent materiale til anvendelse i behandling ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at behandlingen administrerer materialet via mavesonde.
8. Ketogent materiale til anvendelse i behandling ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at materialet administreres som en parenteral opløsning intravenøst, intraperitonealt eller via anden systemisk vej.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0410266.1A GB0410266D0 (en) | 2004-05-07 | 2004-05-07 | Treatment of apoptosis |
| PCT/GB2005/001699 WO2005107724A1 (en) | 2004-05-07 | 2005-05-04 | Treatment of apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1750686T3 true DK1750686T3 (da) | 2017-05-08 |
Family
ID=32482883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05742563.9T DK1750686T3 (da) | 2004-05-07 | 2005-05-04 | Behandling af akutte refraktære epileptiske anfald med (R)-3-hydroxybutyrat |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US20080249173A1 (da) |
| EP (1) | EP1750686B1 (da) |
| DK (1) | DK1750686T3 (da) |
| GB (1) | GB0410266D0 (da) |
| WO (1) | WO2005107724A1 (da) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2459624C2 (ru) | 2007-04-12 | 2012-08-27 | Риджентс Оф Дзе Юниверсити Оф Миннесота | Защитные композиции от ишемии/реперфузии и способы применения |
| JP5630750B2 (ja) * | 2008-03-18 | 2014-11-26 | 国立大学法人 岡山大学 | 興奮性化学伝達調節剤およびそのスクリーニング法 |
| BR112015024186B1 (pt) | 2013-03-19 | 2023-05-09 | University Of South Florida | Composições e métodos para produção de cetose de elevação e manutenção |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| LT3393655T (lt) | 2015-12-22 | 2021-03-25 | Zogenix International Limited | Fenfluramino kompozicijos ir jų paruošimo būdai |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US20180055789A1 (en) | 2016-08-24 | 2018-03-01 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht2b agonists and methods of using same |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| US10945975B2 (en) | 2016-10-24 | 2021-03-16 | University Of South Florida | Delaying latency to seizure by combinations of ketone supplements |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| WO2019241005A1 (en) | 2018-06-14 | 2019-12-19 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| US20220133652A1 (en) * | 2019-02-25 | 2022-05-05 | Zogenix International Limited | A formulation for improving seizure control |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| RU2743833C1 (ru) * | 2020-08-04 | 2021-02-26 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации | Способ хирургического лечения структурной эпилепсии у детей |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1001209A3 (fr) * | 1987-11-19 | 1989-08-22 | Solvay | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. |
| JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| DK1017379T3 (da) * | 1997-03-17 | 2015-02-16 | Btg Int Ltd | Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| DK1123094T3 (da) * | 1998-09-15 | 2007-08-20 | Btg Int Ltd | Terapeutiske præparater (II) |
| WO2000028985A1 (en) * | 1998-11-19 | 2000-05-25 | Niesen Charles E | Method of treating seizure disorders |
| WO2002062327A2 (en) * | 2001-02-07 | 2002-08-15 | Likhodi Serguei S | Method of treating neurological disorders using acetone derivatives |
| EP1778615A4 (en) * | 2004-07-20 | 2010-01-06 | Btg Int Ltd | OLIGOMERE KETONE COMPOUNDS |
| US9152130B2 (en) * | 2011-01-19 | 2015-10-06 | Ph Technical Labs, Llc | Mobile communication watch utilizing projected directional sound |
-
2004
- 2004-05-07 GB GBGB0410266.1A patent/GB0410266D0/en not_active Ceased
-
2005
- 2005-05-04 EP EP05742563.9A patent/EP1750686B1/en active Active
- 2005-05-04 US US11/579,833 patent/US20080249173A1/en not_active Abandoned
- 2005-05-04 WO PCT/GB2005/001699 patent/WO2005107724A1/en active Application Filing
- 2005-05-04 DK DK05742563.9T patent/DK1750686T3/da active
-
2011
- 2011-12-20 US US13/331,138 patent/US20120157392A1/en not_active Abandoned
-
2013
- 2013-03-25 US US13/849,613 patent/US20130289116A1/en not_active Abandoned
-
2015
- 2015-10-07 US US14/877,325 patent/US20160074349A1/en not_active Abandoned
-
2018
- 2018-12-17 US US16/222,996 patent/US20190247340A1/en not_active Abandoned
-
2022
- 2022-03-14 US US17/654,606 patent/US20220347133A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1750686A1 (en) | 2007-02-14 |
| GB0410266D0 (en) | 2004-06-09 |
| US20220347133A1 (en) | 2022-11-03 |
| US20190247340A1 (en) | 2019-08-15 |
| US20120157392A1 (en) | 2012-06-21 |
| EP1750686B1 (en) | 2017-04-05 |
| US20130289116A1 (en) | 2013-10-31 |
| US20160074349A1 (en) | 2016-03-17 |
| WO2005107724A1 (en) | 2005-11-17 |
| US20080249173A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220347133A1 (en) | Epilepsy treatment employing ketogenic compounds which arrest apoptosis | |
| Hu et al. | Disrupted ionic homeostasis in ischemic stroke and new therapeutic targets | |
| Norwood et al. | Classic hippocampal sclerosis and hippocampal‐onset epilepsy produced by a single “cryptic” episode of focal hippocampal excitation in awake rats | |
| Olney | Excitatory transmitters and epilepsy-related brain damage | |
| Eyles et al. | Neuronal calcium-binding proteins and schizophrenia | |
| Hosford et al. | Ablation of newly generated hippocampal granule cells has disease-modifying effects in epilepsy | |
| Towfighi et al. | Influence of age on the cerebral lesions in an immature rat model of cerebral hypoxia–ischemia: a light microscopic study | |
| Hellier et al. | Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy | |
| Cuevas et al. | Acetyl L-carnitine protects motor neurons and Rohon-Beard sensory neurons against ketamine-induced neurotoxicity in zebrafish embryos | |
| CA2721961A1 (en) | Silk polymer-based adenosine release: therapeutic potential for epilepsy | |
| PT1562566E (pt) | Composições analgésicas compreendendo antagonistas do receptor de nmda e cloreto de benzalcónio | |
| Xu et al. | Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses | |
| Smith et al. | Effect of perinatal administration of ethanol on the CA1 pyramidal cell of the hippocampus and Purkinje cell of the cerebellum: an ultrastructural survey | |
| Dzhala et al. | Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis | |
| US20090197969A1 (en) | Method of reducing brain cell damage or death | |
| Pitkänen et al. | Effects of vigabatrin treatment on status epilepticus-induced neuronal damage and mossy fiber sprouting in the rat hippocampus | |
| EP0935461B1 (de) | Adamantanaminenderivate zur bekämpfung von viren der familie bornaviridae | |
| Yang et al. | Erythropoietin preconditioning suppresses neuronal death following status epilepticus in rats | |
| C Brett et al. | Current therapeutic advances in patients and experimental models of Huntington's disease | |
| DE602004006633T2 (de) | Verwendung von dapson als neuroprotektor bei zerebralinfarkt | |
| WO2003053445A1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
| Matzen et al. | Functional and morphological changes in the dentate gyrus after experimental status epilepticus | |
| McIntyre et al. | Dorsal hippocampal kindling produces long-lasting changes in the origin of spontaneous discharges in the piriform versus perirhinal cortex in vitro | |
| Puica et al. | Ultrastructural aspects concerning the hypothalamus-pituitary complex reactivity following chronic administration of aspartame in juvenile rats | |
| Stanojević et al. | Revising the role of magnesium in epilepsy research and management |